A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age

Influenza Clinical Trial

— MI-CP217  

Official title:

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of MEDI3414 in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00946101
• Other study ID #: MI-CP217
• Secondary ID: HHS/ASPR
• Status: Completed
• Phase: Phase 4
• First received: July 23, 2009
• Last updated: July 15, 2011
• Start date: August 2009
• Est. completion date: March 2010

Study information

• Verified date: July 2011
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to determine the safety and descriptive immunogenicity of the H1N1 influenza vaccine in healthy children.

Description:

The primary objective of this study was to assess the safety and descriptive immunogenicity of a monovalent influenza virus vaccine containing a new 6:2 influenza virus reassortant in healthy children.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 326
• Est. completion date: March 2010
• Est. primary completion date: September 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 2 Years to 17 Years

Eligibility

Inclusion Criteria:

• Male or female, 2 to 17 years of age (not yet reached their 18th birthday) at the time of randomization

• Healthy by medical history and physical exam

• Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act [HIPAA] in the United States of America [USA], European Union [EU] Data Privacy Directive in the EU and written informed assent) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations

• Females of child-bearing potential, (ie, unless premenarchal, surgically sterile [eg, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy], has sterile male partner, or practices abstinence) must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the sexual partner) for 30 days prior to the first dose of investigational product, and must agree to continue using such precautions for 60 days after the second dose of investigational product. In addition, the subject must also have a negative urine or blood pregnancy test at screening and, if screening and Day 1 do not occur on the same day, on the day of vaccination prior to randomization. Investigator judgment is required to assess the childbearing potential of a pre-adolescent or adolescent girl.

• Males, unless not sexually active, must use an effective method of birth control with a female partner and must agree to continue using such contraceptive precautions for at least 30 days after the second dose of investigational product (from Day 1 through Day 59 of the study)

• Subject's legal representative available by telephone

• Subject/subject's legal representative is able to understand and comply with the requirements of the protocol, as judged by the investigator

• Ability to complete follow-up period of 180 days after Dose 2 as required by the protocol

Exclusion Criteria:

• History of hypersensitivity to any component of the investigational product including egg or egg protein, gelatin or arginine, or serious, life-threatening, or severe reactions to previous influenza vaccinations

• History of hypersensitivity to gentamicin

• Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year

• Acute febrile (> 100.0°F oral or equivalent) and/or clinically significant respiratory illness (eg, cough or sore throat) within 14 days prior to randomization

• History of asthma, or in children < 5 years of age, history of recurrent wheezing

• Any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy

• History of Guillain-Barré syndrome

• A household contact who is severely immunocompromised (eg, hematopoietic stem cell transplant recipient, during those periods in which the immunocompromised individual requires care in a protective environment); subject should additionally avoid close contact with severely immunocompromised individuals for at least 21 days after receipt of investigational product

• Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 30 days after the second dose of investigational product (use of licensed agents for indications not listed in the package insert is permitted)

• Use of aspirin or salicylate-containing products within 30 days prior to randomization or expected receipt through 30 days after final vaccination

• Expected receipt of antipyretic or analgesic medication (non-salicylate-containing) on a daily or every other day basis from randomization through 14 days after receipt of each dose of investigational product

• Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after administration of each dose of investigational product

• Receipt of any nonstudy vaccine within 30 days before or after Dose 1 or expected receipt of any nonstudy vaccine within 30 days before or after Dose 2

• Known or suspected mitochondrial encephalomyopathy

• Adolescent subject is pregnant or a nursing mother

• Any condition (eg, chronic cough, allergic rhinitis) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results

• Subject, legal representative, or immediate family member of subject is an employee of the clinical study site or is otherwise in involved with the conduct of the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza

Intervention

Biological:
• MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
0.5 mL: (intranasal sprayer)
• Placebo
Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer

Locations

Country	Name	City	State
United States	Benchmark Research	Austin	Texas
United States	Kentucky Pediatric Research Center	Bardstown	Kentucky
United States	Benchmark Research Ft. Worth	Ft. Worth	Texas
United States	Clinical Research Center of Nevada	Henderson	Nevada
United States	Central Kentucky Research Associates, Inc.	Lexington	Kentucky
United States	Coastal Clinic Research, Inc.	Mobile	Alabama
United States	Meridian Clinical Research	Omaha	Nebraska
United States	Primary Physicians Research, Inc.	Pittsburgh	Pennsylvania
United States	Rochester Clinical Research Inc.	Rochester	New York
United States	Benchmark Research	Sacramento	California
United States	Benchmark Research San Angelo	San Angelo	Texas
United States	California Research Foundation	San Diego	California
United States	Benchmark Research	San Francisco	California
United States	Spartanburg Medical Research	Spartanburg	South Carolina
United States	Sundance Clinical Research	St. Louis	Missouri
United States	Omega Medical Research	Warwick	Rhode Island

Sponsors (2)

Lead Sponsor	Collaborator
MedImmune LLC	Department of Health and Human Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Fever Post Dose 1 (Days 1-8), Defined as an Axillary Temperature = 101°F (38.3°C).	The number of participants with fever between the two treatment groups was compared based on the upper limit of the two-sided 95% exact confidence intervals for the rate difference (Vaccine minus Placebo). The upper limit of the two-sided 95% confidence intervals was evaluated against the prespecified equivalence criterion of 10% which corresponded to the following hypotheses: H0 (null): rate difference = 10%, HA (alternative): rate difference < 10%.	Days 1- 8	Yes
Primary	Number of Participants Who Experience a Post Dose 1 (Day 15) Seroresponse Against the H1N1 Strain in All Participants Regardless of Baseline Serostatus	Seroresponse is described as greater than or equal to a 4-fold rise in hemagglutination inhibition (HAI) titer from baseline. All immunogenicity analyses was based on the immunogenicity population.	Day 1, Day 15	No
Primary	Number of Participants Who Experience a Post Dose 1 (Day 29) Seroresponse Against the H1N1 Strain in All Participants Regardless of Baseline Serostatus	Seroresponse is described as greater than or equal to a 4-fold rise in HAI titer from baseline. All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 29	No
Primary	Number of Participants Who Experience a Post Dose 2 (Day 57) Seroresponse Against the H1N1 Strain in All Participants Regardless of Baseline Serostatus	Seroresponse is described as greater than or equal to a 4-fold rise in HAI titer from baseline. All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 57	No
Secondary	Number of Participants With Any Solicited Symptoms Within 7 Days After Vaccination With Investigational Product, Dose 1	Other solicited symptoms include fever (> 100°F [37.8°C] axillary), runny/stuffy nose, sore throat, cough, headache, generalized muscle aches, decreased activity level (lethargy) or tiredness/weakness, decreased appetite.	Days 1-8	Yes
Secondary	Number of Participants Reporting Adverse Events (AEs) Within 7 Days After Vaccination With Investigational Product, Dose 1		Days 1-8	Yes
Secondary	Number of Participants Using Anti-pyretic and Analgesic Agents Within 7 Days After Vaccination With Investigational Product, Dose 1		Days 1-8	Yes
Secondary	Number of Participants With Any Solicited Symptoms Within 14 Days After Vaccination With Investigational Product, Dose 1		Days 1-15	Yes
Secondary	Number of Participants Reporting AEs Within 14 Days After Vaccination With Investigational Product, Dose 1		Days 1-15	Yes
Secondary	Number of Participants Using Anti-pyretic and Analgesic Agents Within 14 Days After Vaccination With Investigational Product, Dose 1		Days 1-15	Yes
Secondary	Number of Participants With Any Solicited Symptoms Within 7 Days After Vaccination With Investigational Product, Dose 2		Days 29-36	Yes
Secondary	Number of Participants Reporting AEs Within 7 Days After Vaccination With Investigational Product, Dose 2		Days 29-36	Yes
Secondary	Number of Participants Using Anti-pyretic and Analgesic Agents Within 7 Days After Vaccination With Investigational Product, Dose 2		Days 29-36	Yes
Secondary	Number of Participants With Any Solicited Symptoms Within 14 Days After Vaccination With Investigational Product, Dose 2		Days 29-43	Yes
Secondary	Number of Participants Reporting AEs Within 14 Days After Vaccination With Investigational Product, Dose 2		Days 29-43	Yes
Secondary	Number of Participants Using Anti-pyretic and Analgesic Agents Within 14 Days After Vaccination With Investigational Product, Dose 2		Days 29-43	Yes
Secondary	Number of Participants With New Onset Chronic Diseases (NOCDs) Within 28 Days After Vaccination With Investigational Product, Dose 1.	An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of NOCDs included, but were not limited to, diabetes, asthma, autoimmune disease (eg, lupus, rheumatoid arthritis), and neurological disease (eg, epilepsy, autism). Examples of events not considered NOCDs were mild eczema, diagnosis of a congenital anomaly present at study entry, or acute illness (eg, otitis media, bronchitis).	Days 1-29	Yes
Secondary	Number of Participants With Serious Adverse Events (SAEs) Within 28 Days After Vaccination With Investigational Product, Dose 1	SAEs were those AEs that resulted in death; were immediately life threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.	Days 1-29	Yes
Secondary	Number of Participants With NOCDs Within 28 Days After Vaccination With Investigational Product, Dose 2.	An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of NOCDs included, but were not limited to, diabetes, asthma, autoimmune disease (eg, lupus, rheumatoid arthritis), and neurological disease (eg, epilepsy, autism). Examples of events not considered NOCDs were mild eczema, diagnosis of a congenital anomaly present at study entry, or acute illness (eg, otitis media, bronchitis).	Days 29-57	Yes
Secondary	Number of Participants With SAEs Within 28 Days After Vaccination With Investigational Product, Dose 2	SAEs were those AEs that resulted in death; were immediately life threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.	Days 29-57	Yes
Secondary	Number of Participants With NOCDs Within 180 Days Post Final Dose of Investigational Product.	An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of NOCDs included, but were not limited to, diabetes, asthma, autoimmune disease (eg, lupus, rheumatoid arthritis), and neurological disease (eg, epilepsy, autism). Examples of events not considered NOCDs were mild eczema, diagnosis of a congenital anomaly present at study entry, or acute illness (eg, otitis media, bronchitis).	Days 1-209	Yes
Secondary	Number of Participants With SAEs Within 180 Days Post Final Dose of Investigational Product.	SAEs were those AEs that resulted in death; were immediately life threatening; resulted in inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and that, based on appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above.	Days 1-209	Yes
Secondary	Number of Participants Who Achieve a Post Dose 1 (Day 15) HAI Titer Greater Than or Equal to 32 Against the H1N1 Strain in All Participants, Regardless of Baseline Serostatus.	All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 15	No
Secondary	Number of Participants Who Achieve a Post Dose 1 (Day 29) HAI Titer Greater Than or Equal to 32 Against the H1N1 Strain in All Participants, Regardless of Baseline Serostatus.	All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 29	No
Secondary	Number of Participants Who Achieve a Post Dose 2 (Day 57) HAI Titer Greater Than or Equal to 32 Against the H1N1 Strain in All Participants, Regardless of Baseline Serostatus.	All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 57	No
Secondary	Serum HAI Geometric Mean Titers (GMTs) in All Participants, Regardless of Baseline Serostatus, Dose 1 (Day 15)	All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 15	No
Secondary	Serum HAI GMTs in All Participants, Regardless of Baseline Serostatus, Dose 1 (Day 29)	All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 29	No
Secondary	Serum HAI GMTs in All Participants, Regardless of Baseline Serostatus, Dose 2 (Day 57)	All immunogenicity analyses are based on the immunogenicity population.	Day 1, Day 57	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.